Takeda Pharmaceutical (TYO: 4502) and Shire (LSE: SHP) have reached agreement on the Japanese pharma major’s takeover of the Ireland-headquartered rare disease drugmaker.
The deal, which values Shire at £46 billion ($62 billion), will see Takeda shareholders own around 50% of the combined group upon completion, and brings nearer the likely Takeda pursuit of Shire, which has lasted for several weeks, but still requires shareholder's approval.
"We firmly believe that this combination recognizes the strong growth potential of our leading products and innovative pipeline and is in the best interests of our shareholders, our patients and the communities we serve"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze